Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01392443
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : July 6, 2018
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The objective of this study is to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume will also be assessed.

Condition or disease Intervention/treatment Phase
Primary Myelofibrosis (MF) Post-Polycythemia Vera (PV) MF Post-Essential Thrombocythemia (ET) MF Drug: Ruxolitinib Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Actual Study Start Date : August 1, 2011
Actual Primary Completion Date : October 31, 2017
Actual Study Completion Date : October 31, 2017

Arm Intervention/treatment
Experimental: Ruxolitinib
Ruxolitinib is taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), to be increased or decreased per standardized dosing paradigm.
Drug: Ruxolitinib
INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength is 5 mg/tablet INC424 phosphate (free base equivalent). Medication labels will be in the local language and comply with the legal requirements of each country. equivalent).
Other Name: INC424

Primary Outcome Measures :
  1. Efficacy by reduction in spleen volume [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Safety/tolerability of INC424 [ Time Frame: Frequency, duration and severity of adverse events ]
    based on frequency, duration and severity of adverse events

  2. patient reported outcomes [ Time Frame: 24 weeks ]
    based on patient-directed quality of life questionnaires

  3. Duration of response [ Time Frame: about 3 years ]
    reduction in spleen volume

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 18 years or older
  2. Diagnosis of primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF
  3. Enlarged spleen, measuring 5 cm or greater from the costal margin
  4. Must have two or more of the following risk factors:

    1. Over 65 years old
    2. Have the following symptoms often associated with MF: loss of weight, fever, night sweats
    3. Have a low red blood cell count (anemia - hemoglobin < 10 g/dL)
    4. Have a high white blood cell count (history of white blood cell count > 25,000/uL)
    5. Have high circulating blasts (> or = 1%) as measured by blood tests
  5. Should have circulating blasts <10% (as measured by blood tests)
  6. Should be capable of self-care
  7. Should have adequate bone marrow reserve
  8. Should not have the option of stem cell transplantation
  9. Should discontinue any prior or ongoing treatment for myelofibrosis prior to entering the study
  10. Had no prior treatment with another JAK inhibitor

Exclusion Criteria:

  1. Does not have adequate liver or kidney function (as measured by blood tests)
  2. Has an active infection (bacterial, viral, etc.)
  3. Has active hepatitis A, B, or C or positive for HIV
  4. Has another cancer that needs active intervention
  5. Had a history of bleeding disorder
  6. Had a history of very low platelet counts (as measured by blood tests) not related to treatment of MF
  7. Had radiation of the spleen within 1 year of joining the study
  8. Does not have adequate heart function
  9. Sufficient time has elapsed between stopping previous treatment for MF and joining the study
  10. Females who are pregnant or breast-feeding
  11. Not able to sign informed consent
  12. Has any other active medical conditions that the doctor deems may compromise your safety or ability to join in the study

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01392443

China, Beijing
Novartis Investigative Site
Beijing, Beijing, China, 100730
China, Guangdong
Novartis Investigative Site
Guangzhou, Guangdong, China, 510080
China, Hubei
Novartis Investigative Site
Wuhan, Hubei, China, 430030
China, Jiangsu
Novartis Investigative Site
Nanjing, Jiangsu, China, 210029
Novartis Investigative Site
Suzhou, Jiangsu, China, 215006
China, Sichuan
Novartis Investigative Site
Chengdu, Sichuan, China, 610041
China, Tianjin
Novartis Investigative Site
Tianjin, Tianjin, China, 300020
China, Zhejiang
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310003
Novartis Investigative Site
Jinan, China, 250012
Novartis Investigative Site
Shanghai, China, 200025
Novartis Investigative Site
Nagoya, Aichi, Japan, 466-8560
Novartis Investigative Site
Fukuoka city, Fukuoka, Japan, 812-8582
Novartis Investigative Site
Maebashi-city, Gunma, Japan, 371-8511
Novartis Investigative Site
Kanazawa-city, Ishikawa, Japan, 920-8641
Novartis Investigative Site
Tsu-city, Mie, Japan, 514-8507
Novartis Investigative Site
Suita-city, Osaka, Japan, 565-0871
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8655
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-0023
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-8582
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 03080
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 06351
Novartis Investigative Site
Seoul, Korea, Republic of, 03722
Novartis Investigative Site
Seoul, Korea, Republic of, 06591
Novartis Investigative Site
Kaohsiung, Taiwan, 833
Novartis Investigative Site
Taipei, Taiwan, 10048
Novartis Investigative Site
Taoyuan, Taiwan, 333
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01392443     History of Changes
Other Study ID Numbers: CINC424A2202
First Posted: July 12, 2011    Key Record Dates
Last Update Posted: July 6, 2018
Last Verified: July 2018

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Additional relevant MeSH terms:
Primary Myelofibrosis
Polycythemia Vera
Thrombocythemia, Essential
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders